Study of Chemotherapy and Patient Health Outcomes for Nausea and Emesis (0000-041) (C-PHONE)

Merck Sharp & Dohme (MSD)

Status: Completed

Conditions: Chemotherapy Induced Nausea and Vomiting

Treatments: Behavioral: Disease Management Assessment

Study type: Interventional

Funder types: Industry

Identifiers

NCT00211601

2005_072

041

0000-041

Details and patient eligibility

About

The purpose of this study is to assess whether timely feedback to providers on patient experiences with delayed chemotherapy induced nausea and vomiting (CINV) lead to differences in patient outcomes for subsequent cycles.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Highly or moderately emetogenic chemotherapy planned for at least 2 cycles

Exclusion criteria

• Concurrent other anti-cancer therapy (e.g. radiation, hormone, etc.); vomiting during the 24 hours prior to first chemotherapy cycle; having a disease/condition or taking medication that may cause emesis